Tiny Health is breaking gut care out of its lane.
What’s happening: The microbiome intelligence company secured a $33M Series B to map the gut’s role in IBD, menopause, GLP-1s, and cancer care.
Inside story. Growing beyond infant microbiome tracking, Tiny Health’s platform explores how gut and vaginal microbiomes shape health across life stages.
Pairing metagenomic sequencing, AI, and longitudinal data to identify microbes at strain level, its at-home tests have surfaced metabolic, immune, and pathogen signals for ~200K patients and 6K+ practitioners.
Care Engine. As research uncovers gut-communicating axes for the brain, muscle, and skin, Tiny will scale its B2B platform and AI health advisor to make connections for healthier aging.
With more than $550B per year spent on chronic conditions linked to the gut microbiome, it wants to build “the infrastructure for an entire industry” — turning individual microbiome results into personalized, science-backed actions that get smarter as data grows.
Punchline: As platforms like Tiny Health and Viome move microbiome testing from tracking to clinical intelligence, consumers are securing their place at integrated care’s cutting edge.
